For more than a century, CSL Behring has earned a reputation as an organization driven to care for patients with rare and serious diseases. We are a company known for keeping our promises – to ...
Morgan Stanley initiated coverage of CSL (CSLLY) with an Overweight rating and A$313 price target A “solid revenue growth outlook” and margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback